Evidence map›Paper›PMID 31844767›Full record

ArticleHeliyon2019

Co-encapsulation of thymoquinone with docetaxel enhances the encapsulation efficiency into PEGylated liposomes and the chemosensitivity of MCF7 breast cancer cells to docetaxel.

Fadwa Odeh, Randa Naffa, Hanan Azzam, Ismail S Mahmoud, Walhan Alshaer, Abeer Al Bawab, Said Ismail

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Fadwa OdehDepartment of Chemistry, The University of Jordan, Amman, Jordan.
Randa NaffaFaculty of Medicine, The University of Jordan, Amman, Jordan.
Hanan AzzamHamdi Mango Center for Scientific Research, The University of Jordan, Amman, Jordan.
Ismail S MahmoudDepartment of Medical Laboratory Sciences, The Hashemite University, Zarqa, Jordan.
Walhan AlshaerCell Therapy Center, The University of Jordan, Amman, Jordan.
Abeer Al BawabDepartment of Chemistry, The University of Jordan, Amman, Jordan.
Said IsmailFaculty of Medicine, The University of Jordan, Amman, Jordan.
University of Jordan · JOHashemite University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combinatorial therapeutic strategies to eradicate tumors can be superior to a single therapeutic modality. Docetaxel (DT) has been approved for the treatment of local or metastasized breast cancer alone or in combination with other chemotherapeutic agents. Thymoquinone (TQ) originated from the seeds of

Indexed as

Breast cancerCancer researchCombination therapyDelivery systemDocetaxelLiposomesPharmaceutical scienceThymoquinone

Identifiers

PMID31844767
PMCPMC6895652
OpenAlexW2989854294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.